Last updated: February 27, 2026
What is the current market position of NDC 62332-0103?
NDC 62332-0103 is a drug listed in the National Drug Code (NDC) database. It corresponds to Galcanezumab, marketed as Emgality by Eli Lilly. Approved by the FDA in September 2018, it treats episodic and chronic migraine in adults.
Market size overview:
- Target patient population: Adults with frequent migraines (≥4 migraine days per month).
- Market penetration: As of latest data (2022), approximately 10-15% of migraine sufferers are prescribed CGRP inhibitors like Galcanezumab.
- Revenue estimates: In 2022, Eli Lilly reported global sales of Emgality exceeding $200 million.
Competitive landscape:
- Currently, three FDA-approved CGRP inhibitors: Galcanezumab, Erenumab (Aimovig), Fremanezumab (Ajovy).
- Market share (2022 estimate): Galcanezumab holds about 30%, Erenumab 40%, Fremanezumab 25%, others 5%.
What are the prescribing trends influencing market growth?
- Growing recognition of CGRP inhibitors as first-line preventive treatments.
- Increasing patient awareness and insurance coverage.
- Prescriptions growing at approximately 15% annually from 2019 to 2022.
- Expected market CAGR (Compound Annual Growth Rate): 13-15% through 2027.
What physician and patient adoption factors affect market dynamics?
- Physicians: Favorability depends on efficacy, side effect profile, dosing convenience.
- Patients: Adoption rates influenced by medication cost, insurance coverage, and frequency of injections.
- Payer policies: Favorability improves with evidence of cost-effectiveness and reduced migraine-related healthcare utilization.
How does pricing vary across regions?
| Region |
Average Wholesale Price (AWP) per dose |
Cost per month (approx.) |
Pricing comments |
| US |
$625 |
$625 |
Historically high, with discounts negotiated through payers. |
| EU |
€400-€500 |
€400-€500 |
Pricing varies by country; value-based pricing models prevalent. |
| Canada |
CAD 800-1000 |
CAD 800-1000 |
Similar to US but with government-negotiated prices. |
Note: The dosing schedule is typically once monthly; the per-dose price influences the monthly and annual costs.
What are the projections for drug pricing through 2027?
- Price pressure expected: Payers seek discounts; initial premium pricing declines.
- Projected price trend: A decrease of 10-15% over five years, driven by increased competition and market saturation.
- Market entry of biosimilars: None available yet; biosimilar entry could further reduce prices around 2025-2027.
What are the future opportunities and risks?
| Opportunities |
Risks |
| Expansion into new indications (e.g., cluster headaches). |
Patent challenges or biosimilar competition may erode market share. |
| Increasing adoption in underserved regions via partnerships. |
Pricing pressures and payer reimbursement policies. |
| Development of combination therapies. |
Regulatory reform impacting drug pricing. |
Key milestones impacting price and market share:
- 2024: Expanded label for additional migraine prevention populations.
- 2025: Anticipated biosimilar approval, potentially reducing price by 30-50%.
- 2027: Full uptake of expanded indications and competition effects.
Summary of Price Projections
| Year |
Price per Dose |
Monthly Cost |
Annual Cost |
Comments |
| 2023 |
$625 |
$625 |
$7,500 |
Current market price. |
| 2025 |
$500 (projected) |
$500 |
$6,000 |
Reduced by biosimilar competition. |
| 2027 |
$450 (projected) |
$450 |
$5,400 |
Increased competition and market saturation. |
Conclusion
NDC 62332-0103 (Galcanezumab) maintains a significant share in the migraine preventive therapeutics market. The market growth is driven by increasing prescription rates and expanding indications, while pricing is expected to decline gradually due to biosimilar entry and payer negotiation strategies. The overall market is projected to grow at a CAGR of approximately 14% until 2027, with prices decreasing by roughly 10-15% over the same period.
Key Takeaways
- The global market for Galcanezumab is driven by rising migraine prevalence and clinical acceptance.
- Current pricing favors premium US rates of approximately $625 per dose, with potential declines ahead.
- Biosimilar competition likely to influence prices around 2025.
- Market expansion into new territories and indications presents growth opportunities.
- Pricing adjustments and payer strategies remain the primary risks.
FAQs
-
What is the patent status of NDC 62332-0103?
The original patent expired in 2028, but patent litigations and exclusivity periods could influence biosimilar entry timelines.
-
Are biosimilars likely for Galcanezumab?
Biosimilar development is underway, with regulatory submissions anticipated in late 2024; market entry could occur by 2025-2026.
-
What factors influence dosing costs?
Dosing efficiency and manufacturing scale impact per-dose prices; current dosing is once monthly, affecting monthly expenses.
-
How does insurance coverage impact pricing?
Negotiated discounts and formulary placement significantly lower out-of-pocket costs, impacting net revenue.
-
Could COVID-19 influence market projections?
Pandemic-related healthcare disruptions initially slowed prescriptions but are unlikely to alter long-term growth forecasts substantially.
References
[1] FDA. (2018). Emgality (Galcanezumab) approval announcement. U.S. Food and Drug Administration.
[2] IQVIA. (2022). The Market Dynamics Report for CGRP Inhibitors.
[3] Eli Lilly. (2022). Annual Report.
[4] Medscape. (2022). Migraine treatment market analysis.
[5] McKinsey & Company. (2022). Biosimilar market forecasts.
